Lamivudine and Entecavir for Acute Hepatitis B: A Systematic Review and Meta-Analysis.
acute Hepatitis B
entecavir
lamivudine
nucleoside analogue
viral hepatitis
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
10 Nov 2023
10 Nov 2023
Historique:
received:
28
09
2023
revised:
25
10
2023
accepted:
30
10
2023
medline:
27
11
2023
pubmed:
25
11
2023
entrez:
25
11
2023
Statut:
epublish
Résumé
Acute hepatitis B infection is associated with severe liver disease and chronic sequelae in some cases. The purpose of this review was to determine the efficacy of nucleoside analogues (NA) (lamivudine versus entecavir) compared to placebo or no intervention for treating acute primary HBV infection. A meta-analysis for drug intervention was performed, following a fixed-effect model. Randomized controlled trials (RCTs) and quasi-randomized studies that evaluated the outcomes of NA in acute hepatitis B infection were included. The following outcomes were considered: virological cure (PCR negative), elimination of acute infection (seroconversion of HBsAg), mortality, and serious adverse events. Five trials with 627 adult participants with severe acute hepatitis B defined by biochemical and serologic parameters were included. Virological cure did not favor any intervention: OR 0.96, 95% CI 0.54 to 1.7 ( There is insufficient evidence that NA obtain superior efficacy compared with placebo/standard-of-care in patients with acute viral hepatitis, based on low quality evidence.
Sections du résumé
BACKGROUND
BACKGROUND
Acute hepatitis B infection is associated with severe liver disease and chronic sequelae in some cases. The purpose of this review was to determine the efficacy of nucleoside analogues (NA) (lamivudine versus entecavir) compared to placebo or no intervention for treating acute primary HBV infection.
METHODS
METHODS
A meta-analysis for drug intervention was performed, following a fixed-effect model. Randomized controlled trials (RCTs) and quasi-randomized studies that evaluated the outcomes of NA in acute hepatitis B infection were included. The following outcomes were considered: virological cure (PCR negative), elimination of acute infection (seroconversion of HBsAg), mortality, and serious adverse events.
RESULTS
RESULTS
Five trials with 627 adult participants with severe acute hepatitis B defined by biochemical and serologic parameters were included. Virological cure did not favor any intervention: OR 0.96, 95% CI 0.54 to 1.7 (
CONCLUSION
CONCLUSIONS
There is insufficient evidence that NA obtain superior efficacy compared with placebo/standard-of-care in patients with acute viral hepatitis, based on low quality evidence.
Identifiants
pubmed: 38005918
pii: v15112241
doi: 10.3390/v15112241
pmc: PMC10675181
pii:
doi:
Substances chimiques
Lamivudine
2T8Q726O95
Antiviral Agents
0
Hepatitis B Surface Antigens
0
entecavir
5968Y6H45M
DNA, Viral
0
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
World J Gastroenterol. 2015 Nov 14;21(42):11941-53
pubmed: 26576083
Hepatology. 2023 Sep 1;78(3):976-990
pubmed: 37125643
Scand J Infect Dis. 2009;41(9):703-4
pubmed: 19544224
Emerg Microbes Infect. 2015 May;4(5):e30
pubmed: 26060603
World J Hepatol. 2016 Feb 18;8(5):273-81
pubmed: 26925201
Bone Marrow Transplant. 2003 Mar;31(6):515-6
pubmed: 12665850
Eur Rev Med Pharmacol Sci. 2014;18(9):1333-43
pubmed: 24867511
Indian J Med Microbiol. 2016 Apr-Jun;34(2):166-72
pubmed: 27080767
Clin Pharmacokinet. 1999 Jan;36(1):41-66
pubmed: 9989342
J Hepatol. 2003;39 Suppl 1:S139-42
pubmed: 14708692
Hepatology. 2018 Apr;67(4):1560-1599
pubmed: 29405329
Gastroenterol Hepatol. 2020 Nov;43(9):559-587
pubmed: 32778356
J Hepatol. 2017 Aug;67(2):370-398
pubmed: 28427875
J Clin Epidemiol. 2011 Apr;64(4):383-94
pubmed: 21195583
Hepatology. 2007 Jan;45(1):97-101
pubmed: 17187417
Hepatol Int. 2016 Jan;10(1):1-98
pubmed: 26563120
J Viral Hepat. 2014 Oct;21(10):744-50
pubmed: 24329913
Cochrane Database Syst Rev. 2017 Mar 21;3:CD011645
pubmed: 28321877
Vopr Virusol. 2003 May-Jun;48(3):40-4
pubmed: 12894480
Am J Hematol. 2002 Feb;69(2):151
pubmed: 11835357
Open Forum Infect Dis. 2017 Dec 20;4(4):ofx231
pubmed: 29302605
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Hepatology. 2009 May;49(5 Suppl):S4-S12
pubmed: 19399804
J Viral Hepat. 2004 Sep;11(5):427-31
pubmed: 15357647
Drugs. 1999 Jul;58(1):101-41
pubmed: 10439933
J Viral Hepat. 2006 Apr;13(4):256-63
pubmed: 16611192
Leuk Res. 2011 Jun;35(6):e67-8
pubmed: 21168208
Clin Mol Hepatol. 2019 Jun;25(2):93-159
pubmed: 31185710
Dig Dis Sci. 2010 Mar;55(3):775-83
pubmed: 19957031
Rev Esp Enferm Dig. 2013 Jan;105(1):57-8
pubmed: 23548017
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
Hepatology. 2009 May;49(5 Suppl):S13-21
pubmed: 19399811